Αναζήτηση αυτού του ιστολογίου

Δευτέρα 6 Νοεμβρίου 2017

A case of segmental stiff skin syndrome treated with systemic losartan

Abstract

Stiff skin syndrome (SSS) is a rare, autosomal dominant cutaneous disorder with progressive, symmetric, sclerotic skin changes of the shoulders, hips, and thighs. In a recent publication, a distinct segmental variant of SSS was proposed. In this report we discuss the case of a boy with segmental SSS and review the current literature.



Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma

Abstract
Background
The GLARIUS trial which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) as compared to standard temozolomide (TMZ) in the first-line therapy of MGMT-nonmethylated glioblastoma showed that progression-free survival was significantly prolonged by BEV/IRI while overall survival was similar in both arms. The present report focusses on quality of life (QoL) and Karnofsky performance score (KPS) during the whole course of the disease.
Patients and methods
Patients (n=170) received standard radiotherapy and were randomized (2:1) for BEV/IRI or standard TMZ. At least every three months KPS was determined and QoL was measured using the EORTC-QLQ C30 and BN20 questionnaires. A generalized estimating equation model (GEE) evaluated differences in the course of QoL and KPS over time. Also, the time to first deterioration and the time to postprogression deterioration was analyzed separately.
Results
In all dimensions of QoL and KPS, GEE analyses and time to first deterioration analyses did not detect significant differences between the treatment arms. At progression, 82% of patients receiving second-line therapy in the standard arm received BEV second-line therapy. For the dimensions motor dysfunction and headaches, time to postprogression deterioration was prolonged in the standard arm receiving crossover second-line BEV in the vast majority of patients at the time of evaluation.
Conclusions
GLARIUS did not find indications for a BEV-induced detrimental effect on QoL in first-line therapy of MGMT-nonmethylated GBM patients. Moreover, GLARIUS provided some indirect corroborative data supporting the notion that BEV may have beneficial effects upon QoL in relapsed GBM.

Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis

Twenty years ago, Patchell and colleagues1 demonstrated that whole-brain radiotherapy (WBRT) mitigates relapse both in the surgical bed and elsewhere in the brain and prevents death from neurologic causes in patients with resected brain metastasis. Therefore, postoperative WBRT became the standard of care.

Role of Dectin-1 receptor on cytokine production by human monocytes challenged with Paracoccidioides brasiliensis

Abstract

Fungal recognition by Dectin-1 receptor triggers a series of cellular mechanisms involved in a protective activation of the immune system. In this study we aimed to evaluate the participation of Dectin-1 receptor in the induction of IL-8, TNF-α, IL-12, IL-10 and IL-17A secretion by human monocytes activated with different cytokines, and challenged in vitro with Paracoccidioides brasiliensis (P. brasiliensis). Our results show that monocytes challenged with P. brasiliensis (Pb265) are able to produce IL-12, IL-8, IL-17, IL-10, and TNF-α. Dectin-1 receptor blockage decreased the IL-12, IL-17, IL-10, and TNF-α levels indicating the participation of such receptor in the induction of these cytokines. Only IL-8 production was not affected by the blockage. Cells activation with different cytokines showed that GM-CSF was able to induce secretion of all cytokines and the receptor blockage prior to the challenge also decreased the cytokine secretion, except IL-8. Monocytes activated with TNF-α promoted IL-8, IL-10, and TNF-α production, while stimulation with IFN-γ promoted mainly IL-12 and TNF-α. Thus, these findings bring new and important knowledge about Dectin-1 participation in cytokines production by monocytes challenged with Pb265.

This article is protected by copyright. All rights reserved.



Correlation between Fungal Sensitization in Childhood Persistent Asthma and Disease Severity

Abstract

Background

Fungal sensitization in adults is associated with severe asthma but prevalence and clinical significance of fungal sensitization remains unclear in paediatric population.

Objective

To study association of fungal sensitization with disease severity in children with persistent asthma

Patients and Methods

One hundred children with persistent asthma in age group 7-15 years, symptom duration >2 years and forced expiratory volume in first second >50% of expected were enrolled. Skin prick test (SPT) to 8 fungal antigens and total serum IgE were done. Fungal sensitization was described as positive SPT (wheel diameter more than 3mm larger than the negative control) to any of the fungal antigens and total serum IgE >200ng/ml.

Results

Seventeen patients showed evidence of fungal sensitization, of which, six demonstrated sensitization to multiple fungi. 17.6% patients with fungal sensitization had severe asthma as compared to 2.4% patients without fungal sensitization (p value 0.032). Significant increase in family history of allergic comorbidities was noted among patients with fungal sensitization (47.1% vs 21.7%, p value 0.03). The most common implicated organism in fungal sensitized patients was Aspergillus flavus (47.1%).

Conclusion

The results of this study, a first among Indian children with asthma, suggest that children with fungal sensitization have more severe asthma as compared to children without fungal sensitization.

This article is protected by copyright. All rights reserved.



Posaconazole Liquid vs Tablet Formulation in Lung Transplant Recipients

Summary

Background

Posaconazole is an extended-spectrum triazole antifungal used in the treatment and prophylaxis of Aspergillus infections. It is available as oral suspension (POS-Liq) and delayed-release tablets (POS-Tab).

Objectives

The aim of this longitudinal, retrospective study was to compare the clinical effectiveness, toxicity, and pharmacokinetics of POS-Liq vs. POS-Tab in lung transplant recipients (LTx-recipients), who were treated with both formulations subsequently.

Patients/ Methods

Twenty-four consecutive LTx-recipients with 191 documented posaconazole trough levels (PTLs) for POS-Liq or POS-Tab were included. The administered daily doses were 300mg for POS-Tab and 600mg (prophylaxis) or 800mg (therapy) for POS-Liq. Target PTLs were ≥700ng/ml (prophylaxis) and ≥1250ng/ml (therapy).

Results

The overall prophylactic and therapeutic response rates were 78% and 67%, respectively. No cases of hepatotoxicity or QT-prolongation were observed with either formulation. The achieved target PTLs were doubled under POS-Tab compared to POS-Liq with fewer risk factors for sub-therapeutic PTLs. Concomitant administration of POS-Tab significantly reduced the tacrolimus concentration-to-dose ratio (p=0.001).

Conclusions

We suggest the use of POS-Tab is appropriate for prophylaxis and therapy of Aspergillus infections in LTx-recipients, since POS-Tab displayed more reliable PTLs with no added adverse events. However, we recommend regular drug monitoring for POS-Liq and for therapy with POS-Tab and that immunosuppressant levels are monitored closely when the posaconazole formulation is switched.

This article is protected by copyright. All rights reserved.



Is MBL serum concentration a reliable predictor for recurrent vulvovaginal candidiasis?

Summary

Background

Recurrent vulvovaginal candidiasis (RVVC) is acommon opportunistic, mucosal fungal infection, predominantly caused by the fungus Candida albicans.Mannose-binding lectin (MBL) is an acute-phase protein that plays a key role in the innate immunity defense against infectious disease.

Objectives

The present study was conducted to evaluate the relationship between the MBL serum level and the relative expression of MBL mRNA in RVVC using real-time PCR for the first time.

Patients/Methods

The case-control study included 40 female participants suffering from RVVC and 40 healthy individuals. The MBL serum level was measured using a commercial ELISA kit. The relative mRNA expression of the MBL gene was quantified using real-time PCR. Data analysis was done by SPSS software.

Results

The MBL concentration was significantly higher in the participants suffering from RVVC compared to the control group (0.330 ng/ml versus 0.253 ng/ml). The prognostic value (P<0.001) for RVVC diagnosis has been calculated. Quantitative RT-PCR results from 35 samples showed a low to significant values for mRNA levels corresponding to MBL gene expression (1-352 folds) (P<0.001).

Conclusion

The results of this study suggest that MBL plays a main role in the innate immunity and it is also affected by environmental factors and other genetic variations. Therefore, the MBL gene expression profile does not reflect precise phenotypic levels in the serum.

This article is protected by copyright. All rights reserved.



Treatment of Palmar Hyperhidrosis by Peripheral Nerve Block at the Wrist With Botulinum Toxin

Publication date: Available online 6 November 2017
Source:Actas Dermo-Sifiliográficas (English Edition)
Author(s): A. de Quintana-Sancho, M.T. Conde Calvo




First Sonographic Description of Idiopathic Cutaneous Angiosarcoma of the Head and Neck

Publication date: Available online 6 November 2017
Source:Actas Dermo-Sifiliográficas (English Edition)
Author(s): Pedro Vilas Boas, Antonio Ruedas-Martínez, Ofelia Baniandrés-Rodriguez, Cristina Ciudad-Blanco




Tumor With a 40-Year History

Publication date: Available online 6 November 2017
Source:Actas Dermo-Sifiliográficas (English Edition)
Author(s): P. García-Montero, J.M. Segura Palacios, M.de Troya Martín




Unilateral Digital Hyperpigmentation in a Teenager

Publication date: Available online 6 November 2017
Source:Actas Dermo-Sifiliográficas (English Edition)
Author(s): L. Campos Muñoz, A. Fueyo Casado, E. López Bran




Acquired Port-Wine Stain (Fegeler Syndrome): A Report of 3 Cases

Publication date: Available online 6 November 2017
Source:Actas Dermo-Sifiliográficas (English Edition)
Author(s): J.F. Millán-Cayetano, J. del Boz, P. García-Montero, M. de Troya-Martín




Stony-hard Subcutaneous Nodule

Publication date: Available online 6 November 2017
Source:Actas Dermo-Sifiliográficas (English Edition)
Author(s): J.F. Millán-Cayetano, I.C. Abitei, P. García-Montero, L. Padilla-España




Intense Local Reaction at the Sites of Injection of Lipolytic Mesotherapy

Publication date: Available online 6 November 2017
Source:Actas Dermo-Sifiliográficas (English Edition)
Author(s): S. Córdoba, E. Rojas, A. Garrido-Ríos, J. Borbujo




Three-Dimensional Strawberry Tattoo

Publication date: Available online 6 November 2017
Source:Actas Dermo-Sifiliográficas (English Edition)
Author(s): A. Imbernón-Moya, E. Fernández-Cogolludo, M.Á. Gallego-Valdés




Lichen Aureus: A Congenital Case?

Publication date: Available online 6 November 2017
Source:Actas Dermo-Sifiliográficas (English Edition)
Author(s): O. Corral-Magaña, J. Escalas Taberner, A. Bauzá Alonso, A. Martin-Santiago




Robotic-assisted DIEP flap harvest: a feasibility study on cadaveric model

The DIEP flap has reduced the incidence of abdominal wall complications compared to the TRAM flap [1]. However, this risk still remains [1-2] because the anterior sheath of the rectus muscle needs to be incised longitudinally to dissect the deep inferior epigastric vessels. We believe that robotic dissection of the deep inferior epigastric vessels may reduce donor site morbidity by preserving the anterior sheath of the rectus muscle as much as possible. The aim of this study was to assess the technical feasibility of DIEP flap harvest with robotically assisted dissection of the deep inferior epigastric vessels.

Non-invasive cardiac imaging in patients with systemic amyloidosis: a practical approach with emphasis on clinical contribution of bone-seeking radiotracers

Abstract

Purpose

Cardiac amyloidosis is a rare and still underdiagnosed disease leading a poor prognosis. We reviewed the literature regarding non-invasive imaging of cardiac amyloidosis (i.e., echocardiography, magnetic resonance, and nuclear medicine imaging) with special attention to the clinical contribution of bone-seeking radiotracers.

Methods

We performed a PubMed and Scopus literature search using keywords related to imaging of cardiac involvement in systemic amyloidosis. In particular, a review of studies published in the English literature between 2002 and 2017 dealing with clinical contribution of in vivo nuclear medicine imaging using bone-seeking radiotracers has been performed; studies that do not clearly report final diagnoses have been excluded.

Results

Interest for cardiac amyloidosis imaging has raised in the last years; in particular, about 20 recent studies evaluating imaging with bone-seeking radiotracers have been considered for the review. Echocardiography represents the first imaging approach, although its sensitivity (in the early stage) and specificity are limited. Magnetic resonance imaging can show highly suggestive signs for cardiac amyloidosis. Imaging with bone-seeking radiotracers has high accuracy in revealing cardiac amyloidosis etiology—both sensitivity and specificity reach 100% in selected groups of patients—and performs better than other imaging modalities in revealing the early cardiac amyloidosis. PET radiotracers' contribution is still under investigation.

Conclusions

Imaging can aid in differentiating cardiac amyloidosis from other diseases providing prognostic information. Bone-seeking radiotracers can establish the type of amyloidosis, even without performing biopsy, in a large part of patients, and are able to early detect cardiac involvement in subjects with transthyretin gene mutations.



Robotic-assisted DIEP flap harvest: a feasibility study on cadaveric model

Publication date: Available online 6 November 2017
Source:Journal of Plastic, Reconstructive & Aesthetic Surgery
Author(s): Samuel Struk, Benjamin Sarfati, Nicolas Leymarie, Antoine Missistrano, Heba Alkhashnam, Françoise Rimareix, Frédéric Kolb, Jean-François Honart




Axilläre und perimamilläre Fox-Fordyce-Erkrankung (apokrine Miliaria) bei einer 19-jährigen Patientin

Zusammenfassung

Die Fox-Fordyce-Erkrankung (FFD), auch bekannt als apokrine Miliaria, ist eine seltene, chronische Dermatose, die durch hautfarbene bis hellbraune oder gelbliche Papeln und Juckreiz v. a. in Bereichen mit apokrinen Drüsen charakterisiert ist. Typischerweise sind postpubertale Mädchen und Frauen zwischen 13 und 35 Jahren betroffen. Die Ätiologie ist bisher nicht gänzlich geklärt, wobei eine hormonelle Komponente diskutiert wird. Des Weiteren wurden verschiedene Exazerbationsfaktoren beschrieben, unter anderem lasergestützte Epilationen sowie eine Hyperhidrose. Die Behandlung der FFD gestaltet sich als relativ schwierig, die bisher beschriebenen Therapien zeigten unterschiedliche Erfolge.



Acne inversa/Hidradenitis suppurativa: Eine Herausforderung für die Zukunft

Zusammenfassung

Acne inversa (AI) ist eine chronisch rezidivierende, entzündliche Dermatose mit dem Charakter einer Systemerkrankung. AI ist durch typische Hautveränderungen in Körperarealen mit apokrinen Drüsen gekennzeichnet. Die Versorgung der AI-Patienten ist in Deutschland nach wie vor unzureichend. Diese Situation lässt sich durch folgende Anstrengungen wahrscheinlich maßgeblich verbessern: 1) die Verkürzung der Zeitspanne zwischen der ersten Manifestation der Erkrankung und Diagnosestellung/Beginn der Therapie; 2) die fundierte Erforschung der AI-Pathogenese mit dem Ziel der Identifizierung von Therapietargets und Blutbiomarkern; 3) die Etablierung einer Methode zur Quantifizierung des Schweregrads der Erkrankung, die sowohl die klinische Beurteilung als auch objektive Laborparameter und die Selbsteinschätzung des Patienten (z. B. Dermatology Life Quality Index [DLQI]) berücksichtigt; 4) die Erarbeitung eines klaren Algorithmus für die interdisziplinäre Behandlung der Patienten, die neben der Therapie der Hautläsionen auch lebensstiländernde Maßnahmen einschließt und die systemischen Veränderungen bei AI berücksichtigt. Dieser Beitrag beschreibt die aktuellen Probleme der medizinischen Versorgung der AI-Patienten und zeichnet Wege auf, wie wir die beschriebenen Ziele erreichen können.



Philosophy of medicine 2017: reviewing the situation

Abstract

In this introduction to a special subsection of Theoretical Medicine and Bioethics comprising separate reviews of the Springer Handbook of the Philosophy of Medicine, The Routledge Companion to Philosophy of Medicine, and The Bloomsbury Companion to Contemporary Philosophy of Medicine, I compare the three texts with respect to their overall organization and their approach to the relation between the science and the art of medicine. I then indicate two areas that merit more explicit attention in developing a comprehensive philosophy of medicine going forward: health economics and systematic relations within the field as a whole. The reviews that follow speak for themselves.



Thomas Schramme and Steven Edwards (eds): Handbook of the philosophy of medicine



Marcum, James A. (ed): The Bloomsbury companion to contemporary philosophy of medicine



How important is woody tissue photosynthesis in EuCahetus dunnii Maiden and Osmanthus fragrans (Thunb.) Lour. under O 3 stress?

Abstract

Numerous studies have demonstrated the negative effects of elevated O3 on leaf photosynthesis. Within trees, a portion of respired CO2 is assimilated by woody tissue photosynthesis, but its response to elevated O3 remains unclear. Saplings of two evergreen tree species, EuCahetus dunnii Maiden (E. dunnii) and Osmanthus fragrans (Thunb.) Lour. (O. fragrans), were exposed to non-filtered air (NF), 100 nmol mol−1 O3 air (E1) and 150 nmol mol−1 O3 air (E2) in open-top chambers from May 5 to September 5, 2016 (8 h a day; 7 days a week) in subtropical China. In this study, O3 fumigation significantly reduced leaf net photosynthesis rate in both two tree species on most measurements. However, compared with leaf net photosynthesis rate, woody tissue gross photosynthesis rate showed less negative response to O3 fumigation and was even stimulated to increase. Refixation rate reflects the utilization efficiency of the respired CO2 by woody tissue photosynthesis. During the experiment period, E1 and E2 both increased refixation rate in O. fragrans compared with NF. Whereas for E. dunnii, E1 increased refixation rate until 81 days after starting of fumigation and then decreased it, and E2 decreased it all the time. Refixation rate had a significant positive correlation with woody tissue chlorophyll contents, indicating that the response of refixation rate to elevated O3 may relate to chlorophyll contents. All these suggested that under O3 fumigation, when atmospheric CO2 uptake and fixation by leaf is limited, woody tissue photosynthesis can contribute more to the total carbon assimilation in trees. The findings help to understand the significance of woody tissue photosynthesis under elevated O3 conditions.



Treatment of synthetic textile wastewater containing dye mixtures with microcosms

Abstract

The aim was to assess the ability of microcosms (laboratory-scale shallow ponds) as a post polishing stage for the remediation of artificial textile wastewater comprising two commercial dyes (basic red 46 (BR46) and reactive blue 198 (RB198)) as a mixture. The objectives were to evaluate the impact of Lemna minor L. (common duckweed) on the water quality outflows; the elimination of dye mixtures, organic matter, and nutrients; and the impact of synthetic textile wastewater comprising dye mixtures on the L. minor plant growth. Three mixtures were prepared providing a total dye concentration of 10 mg/l. Findings showed that the planted simulated ponds possess a significant (p < 0.05) potential for improving the outflow characteristics and eliminate dyes, ammonium-nitrogen (NH4-N), and nitrate-nitrogen (NO3-N) in all mixtures compared with the corresponding unplanted ponds. The removal of mixed dyes in planted ponds was mainly due to phyto-transformation and adsorption of BR46 with complete aromatic amine mineralisation. For ponds containing 2 mg/l of RB198 and 8 mg/l of BR46, removals were around 53%, which was significantly higher than those for other mixtures: 5 mg/l of RB198 and 5 mg/l of BR46 and 8 mg/l of RB198 and 2 mg/l of BR46 achieved only 41 and 26% removals, respectively. Dye mixtures stopped the growth of L. minor, and the presence of artificial wastewater reduced their development.



Hip shape is symmetric, non-dependent on limb dominance and gender-specific: implications for femoroacetabular impingement. A 3D CT analysis in asymptomatic subjects

Abstract

Objective

To determine the reference intervals (RefInt) of the quantitative morphometric parameters of femoroacetabular impingement (FAI) in asymptomatic hips with computed tomography (CT) and determine their dependence on age, side, limb dominance and sex.

Methods

We prospectively included 590 patients and evaluated 1111 hips with semi-automated CT analysis. We calculated overall, side- and sex-specific parameters for imaging signs of cam [omega and alpha angle (α°)] and pincer-type morphology [acetabular version (ACvers), lateral centre-edge angle (LCEA) and cranio-caudal coverage].

Results

Hip shape was symmetrical and did not depend on limb dominance. The 95% RefInt limits were sex-different for all cam-type parameters and extended beyond current abnormal thresholds. Specifically, the upper limits of RefInt for α° at 12:00, 1:30 and 3:00 o'clock positions were 56°, 70° and 58°, respectively, and 45° for LCEA. Acetabular morphology varied between age groups, with a trend toward an LCEA/ACvers increase over time.

Conclusion

Our morphometric measurements can be used to estimate normal hip morphology in asymptomatic individuals. Notably they extended beyond current thresholds used for FAI imaging diagnosis, which was most pronounced for cam-type parameters. We suggest the need to reassess α° RefInt and consider a 60° threshold for the 12:00/3:00 positions and 65-70° for other antero-superior positions.

Key Points

• Hip shape is symmetrical regardless of limb dominance.

• Pincer/cam morphology is frequent in asymptomatic subjects (20 and 71%, respectively).

• LCEA and acetabular version increases with age (5-7° between opposite age groups).

• Femoral morphology is stable after physeal closure (in the absence of pathology).

• Alpha and omega angle thresholds should be set according to sex.



Introspective disputes deflated: the case for phenomenal variation

Abstract

Sceptics vis-à-vis introspection often base their scepticism on 'phenomenological disputes', 'introspective disagreement', or 'introspective disputes' (ID) (see Kriegel in Phenomenol Cogn Sci 6(1):115–136, 2007; Bayne and Spener in Philos Issues 20(1):1–22, 2010; Schwitzgebel in Perplexities of consciousness, MIT Press, Cambridge, 2011): introspectors massively diverge in their opinions about experiences, and there seems to be no method to resolve these issues. Sceptics take this to show that introspection lacks any epistemic merit. Here, I provide a list of paradigmatic examples, distill necessary and sufficient conditions for IDs, present the sceptical argument encouraged by IDs, and review the two main strategies (resolution and containment) to reject such a scepticism. However, both types of strategies are unsatisfactory. In order to save introspection from the looming sceptical threat, I advocate a deflationary strategy, based on either an 'Argument from Perceptual Kinship' or an 'Argument from Ownership'. In the end, there cannot be any genuine IDs, for nothing can fulfil the reasonable conditions for IDs. What looks like IDs may instead be indicators of phenomenal variation. Debates that look like IDs may then arise even if introspection were a perfect method to know one's mind. Thus, scepticism vis-à-vis introspection based on IDs rests on shaky grounds.



Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus

Abstract

Pemphigus is a general term for a rare group of autoimmune diseases which result in the formation of blisters on the skin and oral cavity. Although there is no way to prevent autoimmune diseases, some factors may trigger pemphigus initiation in susceptible individuals or be exacerbated in affected patients. Recognition of these triggers, based on the latest studies and experiences is essential and should be updated every few years. In this study, several triggers, including different drugs and treatments, diseases, vaccines, genetic factors, nutrients, micronutrients, pregnancy, stress, and various other triggers have been discussed. Some possible triggers, such as blood antigens and the effect of seasons have also been discussed briefly. Moreover, some protective factors against pemphigus have been reviewed. Considering the molecular mechanism of pemphigus and immune response alteration during this disease, some possible triggers have been suggested and discussed. Although those triggers may be a real threat, more studies are needed to support these hypotheses.



Investigation of pH effect on cationic solute binding to keratin and partition to hair

Abstract

Objective

In the process of hair treatment, various cationic actives contained in hair care products can be absorbed into hair fiber to modulate the physicochemical properties of hair such as color, strength, style and volume. There have been very limited studies on the binding and partition properties of hair care actives to hair. This study aimed to investigate the pH effects on cationic solute absorption into hair and binding to keratin.

Methods

The keratin binding and hair partition properties of three cationic solutes (theophylline, nortriptyline and amitriptyline) have been measured at different pH using fluorescence spectroscopy and equilibrium absorption experiment. The binding constants, thermodynamic parameters and hair-water partition coefficients determined at different pH were compared and analyzed.

Results

Increasing the pH from 2.0 to 6.0 resulted in the net charge of hair keratin changed from positive to negative. As a consequence, the binding constants of the three cationic solutes with keratin increased with the increasing pH. This correlated with the variation of the electrostatic interaction between cationic solutes and keratin from repulsion to attraction. The positive ΔH and ΔS values indicated that hydrophobic interaction also played a major role in the binding of the three cationic solutes to keratin. There was a good correlation between solutes binding to keratin and hair-water partition of solutes.

Conclusion

It appears that solute binding to hair keratin is driven first by hydrophobic interaction and then by electrostatic interaction. The fitted thermodynamic parameters suggested that hydrophobic interaction dominates for the binding of the three cationic solutes to keratin. That binding of cationic solutes to keratin correlates with the partition of the solutes to hair could provide theoretical guidance for further developing mathematical models of hair partition and penetration properties.

This article is protected by copyright. All rights reserved.



Quality of questionnaires for the assessment of otitis media with effusion in children

Abstract

Introduction

Audiometric tests provide information about hearing in otitis media with effusion (OME). Questionnaires can supplement this information by supporting clinical history-taking as well as potentially providing a standardized and comprehensive assessment of the impact of the disease on a child. There are many possible candidate questionnaires. This study aimed to assess the quality and usability of parent / child questionnaires in OME assessment.

Methods

Fifteen, published questionnaires, commonly used in audiological departments (ABEL, CHAPS, CHILD, COW, ECLiPS, ELF, FAPC, HL-7, LIFE-R Student, LIFE-UK IHP, LittlEARS, LSQ, OM-6, OMQ-14, PEACH) were assessed according to the following 8 criteria: conceptual clarity, respondent burden, reliability, validity, normative data, item bias, ceiling/ floor effects, and administrative burden.

Results

ECLiPS, LittlEARS and PEACH scored highest overall based on the assessment criteria established for this study. None of the questionnaires fully satisfied all 8 criteria. Although all questionnaires assessed issues considered to be of at least adequate relevance to OME, the majority had weaknesses with respect to the assessment of psychometric properties, such as item bias, floor/ceiling effects or measurement reliability and validity. Publications reporting on the evaluation of reliability, validity, normative data, item bias and ceiling/floor effects were not available for most of the questionnaires.

Conclusion

This formal evaluation of questionnaires, currently available to clinicians, highlights three questionnaires as potentially offering a useful adjunct in the assessment of OME in clinical or research settings. These were the ECLiPS, which is suitable for children aged 6 years and older, and either the LittlEARS or the PEACH for younger children. The latter two are narrowly focused on hearing, whereas ECLiPS has a broader focus on listening, language and social difficulties.

This article is protected by copyright. All rights reserved.



Evolution of soft palate surgery techniques for Obstructive Sleep Apnea patients: A comparative study for single level palatal surgeries

Abstract

Objectives

to compare the results of tissue preservation techniques of soft palate surgeries including expansion sphincter pharyngoplasty (ESP) and barbed reposition pharyngoplasty (BRP) for patients suffering from obstructive sleep apnea (OSA) with the traditional uvulopalatopharyngoplasty (UPPP).

Design

interventional comparative study.

Setting

Morgagni- Pierantoni Hospital.

Participants

seventy five patients were included in the study, divided into three groups with 25 patients per group: UPPP, ESP or BRP.

Main outcomes measures

Polysomnography was done for all patients pre- and post-operatively, the post-operative results were recorded at least six months after surgery. All patients were assessed pre-operatively using drug induced sleep endoscopy. Epworth Sleepiness scale and body mass index were registered for all patients before and after surgery.

Results

the mean of pre- and post-operative differences of apnea hypopnea index values were higher in BRP group than ESP: 15.76±14.5 Vs 10.13±5.3; P <0.05 and UPPP groups: 15.76± 14.5 Vs 6.08±5.5; P <0.0005. The mean of differences of oxygen desaturation index values was higher in BRP group than UPPP group: 15.09±17.6 Vs 7.13±6.8; P <0.0005, but not significantly higher than ESP group: 15.09± 17.6 Vs 6.48±7.9; P >0.05. The mean of differences of ESS values was higher in BRP group than ESP group: 5.52 ±4.1 Vs 4.84±3.3; P <0.005 and UPPP groups: 5.52 ±4.1Vs 1.36±1.9; P <0.005. Finally, the pre- and post-operative mean of differences of lowest oxygen saturation values were not statistically significant among the three groups (P >0.05).

Conclusion

BRP can be considered an effective procedure on the basis of the post-operative outcomes. ESP still proves to be a good technique especially when performed by experienced surgeons. Both techniques proved to be superior to UPPP.

This article is protected by copyright. All rights reserved.



Higher prevalence and increased severity of sleep-disordered breathing in male patients with chronic tinnitus: our experience with 173 cases

Tinnitus and sleep are closely related. One of the most important aspects of tinnitus is its association with sleep disturbance. According to the literature, up to 71% of patients with tinnitus report sleep problems (1); furthermore, insomnia is also associated with more distressing tinnitus (2). Conversely, sleep disturbance was proposed as one of the causes of chronic tinnitus (3). The relationship of tinnitus with sleep-disordered breathing (SDB) and obstructive sleep apnea (OSAS) has rarely been mentioned (4). In a recent population-based case-control study, the risk of tinnitus was found to increase 1.36 times in patients with OSAS. However, no detailed grading or severity of SDB (or OSAS) and tinnitus was provided. The purpose of this study was to investigate the exact relationship between tinnitus and SDB and delineate the incidence and severity of SDB in patients with chronic tinnitus; moreover, our study reports the preliminary outcome of tinnitus after intervention with continuous positive airway pressure (CPAP) in selected patients with moderate to severe SDB.

This article is protected by copyright. All rights reserved.



An ENT smartphone Handbook: adopting new practice for induction

There should be continued support and drive for innovation and implementation of smartphone-based access to local guidelines.

This is the first study, that we're aware of, assessing the use of a smartphone-based clinical handbook in ENT surgery.

Use of a smartphone-based handbook is superior to printed or intranet-based guidelines.

Use of smartphone apps can support junior doctors with delivery of care.

Smartphone-based access to guidelines encourage learning and education to improve the induction process for new doctors.

This article is protected by copyright. All rights reserved.



Immunohistochemical expression of vitamin D receptor in melanocytic nevi and cutaneous melanoma. A case-control study

Abstract

Background

Vitamin D (VD) deficiency is associated with higher risk of cancer, possibly due to anti-proliferative, anti-angiogenic, pro-apoptotic, cell-differentiating and anti-invasive effects. The anti-carcinogenic role of VD in melanoma is still a matter of debate. Loss of nuclear and cytoplasmic vitamin D Receptor (VDR) expression in melanoma cells has been reported.

Objective

To analyze VDR immunohistochemical expression in benign dermal nevi (DN) and MM.

Methods

A case-control study evaluated nuclear and cytoplasmic VDR immunohistochemical staining in 54 DN and 55 MM tissue samples.

Results

There was a significantly higher cytoplasmic VDR-positivity in DN compared with MM (59% vs. 16%, P<0.0001). The mean VDR cytoplasmic expression was also higher in DN vs. MM (P<0.0001). No differences in nuclear VDR-positivity were observed between groups, but mean nuclear VDR expression was significantly lower in DN vs. MM (P=0.02). The loss of cytoplasmic VDR in MM was associated with Clark level, Tumor staging and pTNM AJCC staging (P=0.004, P=0.009 and P=0.02, respectively).

Conclusion

Alterations in VDR expression and localization are found in MM compared with DN. Loss of cytoplasmic VDR was associated with melanoma tumor size, suggesting that loss of cytoplasmic VDR may be a prognostic factor.

This article is protected by copyright. All rights reserved.



Prevalence and incidence of chronic spontaneous urticaria in the entire Korean adult population

Abstract

Ethnic differences and temporal trends in the epidemiology of chronic spontaneous urticaria (CSU) are not well understood, especially in East Asia.1-3 The aim of our study was to investigate trends in the prevalence and incidence of CSU among adult Korean subjects from 2006 to 2014 using a nationwide, population-based study.

This article is protected by copyright. All rights reserved.



A systematic review of diagnostic criteria for psoriasis in adults and children: Evidence from studies with a primary aim to develop or validate diagnostic criteria

Abstract

Background

The diagnosis of psoriasis in adults and children is made clinically, for both patient management and the selection of participants in research. Diagnostic criteria provide a structure for clinical assessment, which in turn helps standardise patient recruitment into clinical trials and case definitions in observational studies.

Objective

The aim of this systematic review was to identify and critically appraise the published studies to date that had a primary research aim to develop or validate diagnostic criteria for psoriasis.

Method

A search of Ovid MEDLINE and Ovid Embase was conducted in October 2016. The primary objective was sensitivity and specificity of diagnostic criteria for psoriasis. Secondary objectives included diagnostic recommendations, applicability to children and study characteristics. Diagnostic accuracy studies were critically appraised for risk of bias using the QUADAS-2 tool.

Results

Twenty-three studies met the inclusion criteria.None detailed clinical examination-based diagnostic criteria. The included criteria varied from genetic and molecular diagnostic models to skin imaging, histopathology, questionnaire-based, computer-aided and traditional Chinese medicine criteria. High sensitivity and specificity (>90%) were reported in many studies. However, the study authors often did not specify how criteria would be used clinically or in research. This review identified studies with varyingrisk of bias and due to each study developing separate criteria meta-analysis was not possible.

Conclusion

Clinical examination-based diagnostic criteria are currently lacking for psoriasis. Future research could follow an international collaborative approach and employ high quality diagnostic accuracy study design. Existing and newly developed criteria require validation.

This article is protected by copyright. All rights reserved.



Surgical Management of Penile Lesions Secondary to Foreign Body Reaction: A Case Report and Systematic Review

Abstract
Background
To improve the penile contour, some men choose to undergo implantation or injection of nonbiological materials. Foreign body reactions in penile tissue may produce scarring, deformity, ulceration, necrosis, and even gangrene. Consensus is lacking regarding the most effective surgical procedure for reconstruction of these penile lesions.
Objectives
The authors describe one case study and the first systematic review focusing on reconstructive surgical management for penile lesions secondary to foreign body reaction.
Methods
PubMed, Medline, and Cochrane databases were queried for publications written in English, French, Portuguese, and Spanish from 1951 to May 2017. Multiple search terms were applied.
Results
Of the 3304 articles identified, 51 were included in the systematic review. All were retrospective studies, case series, or case reports. A total of 260 patients underwent surgical procedures, and the complication rate was 37.3%. The scrotal flap technique was performed most frequently (43.4%) and resulted in 65.6% of the total complications observed. One Brazilian case study was also described with an extensive and circumferential ulcer after six mineral oil bolls implant in the penile subcutaneous tissue.
Conclusions
Restoration of the penile shape preserving the functionality and maintaining a good physician-patient relationship may be a challenge. The scrotal pouch may be advantageous for patch grafting of penile soft-tissue lesions, owing to its skin laxity and good blood supply. A less aggressive surgical approach has the benefits of shorter healing time and fewer early complications. Penile injuries are best treated by experienced surgeons on a case-by-case basis with care given to identify the most appropriate treatment.
Level of Evidence: 5


Packaging of Mycobacterium smegmatis bacteria into fecal pellets by the ciliate Tetrahymena pyriformis

Abstract
Mycobacteria are widespread microorganisms that live in various environments, including man-made water systems where they cohabit with protozoa. Environmental mycobacterial species give rise to many opportunistic human infections and can infect phagocytic protozoa. Protozoa such as amoebae and ciliates feeding on bacteria can sometimes get rid of non-digestible or pathogenic material by packaging it into secreted fecal pellets. Usually, packaged bacteria are still viable and are protected against chemical and physical stresses. We report here that mycobacteria can be packaged into pellets by ciliates. The model bacterium Mycobacterium smegmatis survived digestion in food vacuoles of the ciliate Tetrahymena pyriformis and was included in expelled fecal pellets. LIVE/DEAD® staining confirmed that packaged M. smegmatis cells preserved their viability through the process. Scanning and transmission electron microscopy revealed that bacteria are packaged in undefined filamentous and/or laminar substances and that just a thin layer of material seemed to keep the pellet contents in a spherical shape. These results imply that packaging of bacteria is more common than expected, and merits further study to understand its role in persistence and dissemination of pathogens in the environment.

Tellurate enters Escherichia coli K-12 cells via the SulT-type sulfate transporter CysPUWA

Abstract
Soluble forms of tellurium are environmental contaminants that are toxic to microorganisms. While tellurite [Te(IV)] is a well-characterized antimicrobial agent, little is known about the interactions of tellurate [Te(VI)] with bacterial cells. In this study, we investigated the role of sulfate transporters in the uptake of tellurate in Escherichia coli K-12. Mutant strains carrying a deletion of the cysW gene in the CysPUWA sulfate transporter system accumulated less cellular tellurium and exhibited higher resistance to tellurate compared to the wild type strain. Complementation of the mutation restored tellurate sensitivity and uptake. These results indicate that tellurate enters E. coli cells to cause toxic effects via the CysPUWA sulfate transporter.

Intensive cutaneous myiasis due to Musca domestica in a patient with Alzheimer disease: a rare larval infestation in a temperate zone



Synthesis, Photophysical and Computational Study of Novel Coumarin Based Organic Dyes

Abstract

A series of novel coumarin pyrazoline moieties combined with tetrazoles, 3-(1-phenyl-4-(1H-tetrazol-5-yl)-1H-pyrazol-3-yl)-2H-chromen-2-one, 6-chloro-3-(1-phenyl-4-(1H-tetrazol-5-yl)-1H-pyrazol-3-yl)-2H-chromen-2-one, 6-bromo-3-(1-phenyl-4-(1H-tetrazol-5-yl)-1H-pyrazol-3-yl)-2H-chromen-2-one and 6-bromo-3-(1-(4-bromophenyl)-4-(1H-tetrazol-5-yl)-1H pyrazol-3-yl)-2H-chromen-2-one 7(a-d) were designed and synthesized. Single crystal X-ray diffraction and their interactions were studied by Hirshfeld Surface Analysis. Thermal stabilities and electrochemical properties of these compounds were examined from Differential Scanning Calorimetry (DSC), Thermo gravimetric (TGA) and Cyclic Voltametric (CV) studies. Their spectroscopic properties were analysed in various alcohols and general solvents by UV-Vis absorption, fluorescence and time resolved spectroscopy. In addition, the ground and excited state electronic properties were investigated using density functional theory (DFT). The calculated highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) and energy band gap (Eg) values have revealed the effect of substitution of halogens. The substitution has equally affected the ground and excited states of 7(a-d) compounds. The solvatochromism on absorption, fluorescence spectra and fluorescence lifetimes of these compounds were investigated. All these results showed the chromen-2-one of pyrazoline tetrazole derivatives could play an important role in photonic and electronic devices.

This article is protected by copyright. All rights reserved.



Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial

Abstract
Background
Combination pertuzumab, trastuzumab, and docetaxel (D) is considered standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. This post hoc, exploratory analysis of CLEOPATRA study data evaluated the clinical effects of D treatment duration within this regimen. The clinical benefits of pertuzumab and trastuzumab by different durations of D treatment were also evaluated.
Patients and methods
Patients with HER2-positive metastatic breast cancer received trastuzumab and D plus pertuzumab or placebo. Clinical outcomes were analyzed by the number of D cycles that patients received (<6D, 6D, or >6D). Progression-free survival (PFS) and overall survival (OS) for each treatment arm within each D cycle group were estimated using the Kaplan–Meier approach. Time-dependent, multivariate Cox regression was applied to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for HER2-targeted therapy and D cycle groups.
Results
Overall, 804 patients received <6D (n =119), 6D (n =210), or >6D (n =475) cycles. After adjusting for pertuzumab benefits versus placebo (PFS HR = 0.61, 95% CI 0.51–0.74, P <0.0001; OS HR = 0.60, 95% CI, 0.49–0.74, P <0.0001), >6D versus 6D cycles was not associated with statistically significant improvements in PFS (HR = 0.80, 95% CI 0.63–1.01, P =0.0640) or OS (HR = 0.88, 95% CI 0.69–1.12, P =0.3073). Consistent improvements in PFS and OS were observed with pertuzumab versus placebo, irrespective of D duration. The HRs for PFS were 0.395, 0.615, and 0.633 for <6D, 6D, and >6D cycles, respectively (P <0.05 for all D cycle groups). Corresponding HRs for OS were 0.577, 0.700, and 0.612, respectively (P <0.05 for <6D and >6D).
Conclusions
After accounting for pertuzumab benefits, more than six cycles of D treatment was not associated with significant improvements in either PFS or OS compared with six cycles. The addition of pertuzumab to trastuzumab improved clinical outcomes versus trastuzumab plus placebo, regardless of D treatment duration.
ClinicalTrials.gov identifier
NCT00567190.

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy

Abstract
Background
This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-based therapy.
Patients and methods
Patients were randomly assigned (1 : 1) to receive tasquinimod (0.25–1.0 mg/day orally) or placebo. The primary end point was radiologic progression-free survival (rPFS); secondary efficacy end points included: overall survival (OS); PFS on next-line therapy (PFS 2) and symptomatic PFS, assessed using the Brief Pain Inventory (BPI) questionnaire and analgesic use. Quality of life was measured by the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and by the EuroQol-5 Dimension Quality of Life Instrument (EQ-5D). Adverse events were recorded.
Results
A total of 219 patients were screened and 144 patients randomized. The median duration of treatment was 18.7 weeks (range 0.6–102.7 weeks) for the tasquinimod arm and 19.2 weeks (range 0.4–80.0 weeks) for the placebo arm. Median (90% CI) rPFS was 31.7 (24.3–53.7) and 22.7 (16.1–25.9) weeks in the tasquinimod and placebo arms, respectively [HR (90% CI) 0.6 (0.4–0.9), P = 0.0162]. The median OS was not reached because only 14 deaths occurred by the cut-off date. No statistically significant differences between treatment arms were noted for symptomatic PFS, PFS 2, BPI score, FACT-P score, or EQ-5D. The incidence of any treatment emergent adverse event (TEAE) was similar in the tasquinimod and placebo arms (97.2% versus 94.3%, respectively), whereas severe TEAEs (NCI-CTC Grade 3–5) incidence was higher in the tasquinimod group (50.7% versus 27.1%).
Conclusions
Randomized trials testing new drugs as maintenance can be successfully conducted after chemotherapy in castrate-resistant prostate cancer. Maintenance tasquinimod therapy significantly reduced the risk of rPFS by 40%.
ClinicalTrials
gov identifier NCT01732549.

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

Abstract
Background
Immune check-point blockade agents have shown clinical activity in cancer patients but are associated with immune-related adverse events that could limit their development. The aim of this study was to describe the gastrointestinal immune-related adverse events (GI-irAE) in patients with cancer treated with anti-PD-1.
Methods
this is a retrospective study of consecutive adult patients who had a suspected GI-irAE due to anti-PD-1 antibodies between 2013 and 2016. Patients were recruited through a pharmacovigilance registry. Patients' data were reviewed by a multidisciplinary committee that included gastroenterologists, oncologists and a pathologist. Quantitative variables are described by median (range), qualitative variable by frequency (percentage).
Results
Forty-four patients were addressed to a Gastroenterology unit for a suspected GI-IrAE. Twenty patients had a confirmed GI-irAE related to anti-PD-1, which occurred 4.2 months (0.2; 22.1) after the initiation of anti-PD-1. GI-IrAE incidence rate under anti-PD-1 treatment was estimated to be 1.5%. Among patients with GI-IrAE, main symptoms were diarrhoea (n =16, 80%), abdominal pain (n =13, 65%), nausea and vomiting (n =11, 55%), intestinal obstruction (n =1, 5%), and haematochezia (n =2, 10%). No patient had colectomy. Four distinct categories of GI-irAE were observed: acute colitis (n =8, 40%), microscopic colitis (n =7, 35%), upper gastrointestinal tract inflammation (n =4, 20%) and pseudo-obstruction (n =1, 5%). Response rates to corticosteroids were 87.5% (7/8) in acute colitis, 57% (4/7) in microscopic colitis and 75% (3/4) in upper gastrointestinal tract inflammation. Median time to resolution was 36 days (6–172) in acute colitis, and 98 days (42–226) in microscopic colitis.
Conclusion
This study suggests that GI-irAE are different and less frequent with anti PD-1 than with anti CTLA-4.

S-1 as an option for second-line treatment of NSCLC. Is the ‘East Side Story’ applicable in the West?

S-1 is an oral fluoropyrimidine formulation that consists of tegafur (FT), gimeracil, and oteracil in a molar ratio of 1 : 0.4 : 1 [1, 2]. FT is a prodrug of 5-fluorouracil (5-FU), gimeracil serves to maintain the plasma concentration of 5-FU by blocking its degradation, and oteracil limits gastrointestinal toxicity by inhibiting the activation of 5-FU in the gut (Figure 1). In this issue of Annals of Oncology, Nokihara et al. report the results of the EAST-LC trial, a phase III non-inferiority study comparing S-1 (80–120 mg/day, depending on body surface area, for days 1–28 of a 6-week cycle) with docetaxel in 1154 Asian patients with advanced non-small-cell lung cancer (NSCLC) previously treated with at least one platinum-based regimen [3]. The hazard ratio for overall survival (OS) was 0.945, with the upper limit of the 95% confidence interval (1.073) being smaller than the predefined margin of 1.2, thus demonstrating the non-inferiority of S-1. Furthermore, the EORTC QLQ-C30 score for global health status was higher in the S-1 arm. Whereas diarrhea, skin pigmentation, and stomatitis were more common in the patients treated with S-1, the frequency of febrile neutropenia, leukopenia, and alopecia was higher in the docetaxel arm.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)

Abstract
Background
Chemotherapy remains a viable option for the management of advanced non-small-cell lung cancer (NSCLC) despite recent advances in molecular targeted therapy and immunotherapy. We evaluated the efficacy of oral 5-fluorouracil-based S-1 as second- or third-line therapy compared with standard docetaxel therapy in patients with advanced NSCLC.
Patients and methods
Patients with advanced NSCLC previously treated with ≥1 platinum-based therapy were randomized 1 : 1 to docetaxel (60 mg/m2 in Japan, 75 mg/m2 at all other study sites; day 1 in a 3-week cycle) or S-1 (80–120 mg/day, depending on body surface area; days 1–28 in a 6-week cycle). The primary endpoint was overall survival. The non-inferiority margin was a hazard ratio (HR) of 1.2.
Results
A total of 1154 patients (577 in each arm) were enrolled, with balanced patient characteristics between the two arms. Median overall survival was 12.75 and 12.52 months in the S-1 and docetaxel arms, respectively [HR 0.945; 95% confidence interval (CI) 0.833–1.073; P =0.3818]. The upper limit of 95% CI of HR fell below 1.2, confirming non-inferiority of S-1 to docetaxel. Difference in progression-free survival between treatments was not significant (HR 1.033; 95% CI 0.913–1.168; P =0.6080). Response rate was 8.3% and 9.9% in the S-1 and docetaxel arms, respectively. Significant improvement was observed in the EORTC QLQ-C30 global health status over time points in the S-1 arm. The most common adverse drug reactions were decreased appetite (50.4%), nausea (36.4%), and diarrhea (35.9%) in the S-1 arm, and neutropenia (54.8%), leukocytopenia (43.9%), and alopecia (46.6%) in the docetaxel arm.
Conclusion
S-1 is equally as efficacious as docetaxel and offers a treatment option for patients with previously treated advanced NSCLC.
Clinical trial number
Japan Pharmaceutical Information Center, JapicCTI-101155.

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

Abstract
Background
Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement in progression-free survival with cabozantinib versus placebo in patients with progressive medullary thyroid cancer (MTC). Final analysis of overall survival (OS), a key secondary endpoint, was carried out after long-term follow-up.
Patients and methods
EXAM compared cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomized (2:1) to cabozantinib (140 mg/day) or placebo. Final OS and updated safety data are reported.
Results
Minimum follow-up was 42 months. Kaplan–Meier analysis showed a 5.5-month increase in median OS with cabozantinib versus placebo (26.6 versus 21.1 months) although the difference did not reach statistical significance [stratified hazard ratio (HR), 0.85; 95% confidence interval (CI), 0.64–1.12; P = 0.24]. In an exploratory assessment of OS, progression-free survival, and objective response rate, cabozantinib appeared to have a larger treatment effect in patients with RET M918T mutation–positive tumors compared with patients not harboring this mutation. For patients with RET M918T-positive disease, median OS was 44.3 months for cabozantinib versus 18.9 months for placebo [HR, 0.60; 95% CI, 0.38–0.94; P = 0.03 (not adjusted for multiple subgroup analyses)], with corresponding values of 20.2 versus 21.5 months (HR, 1.12; 95% CI, 0.70–1.82; P = 0.63) in the RET M918T–negative subgroup. Median treatment duration was 10.8 months with cabozantinib and 3.4 months with placebo. The safety profile for cabozantinib remained consistent with that of the primary analysis.
Conclusion
The secondary end point was not met in this final OS analysis from the trial of cabozantinib in patients with metastatic, radiographically progressive MTC. A statistically nonsignificant increase in OS was observed for cabozantinib compared with placebo. Exploratory analyses suggest that patients with RET M918T–positive tumors may experience a greater treatment benefit with cabozantinib.
Trial Registration Number
NCT00704730

A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study

Abstract
Background
Intakes of specific fatty acids have been postulated to impact breast cancer risk but epidemiological data based on dietary questionnaires remain conflicting.
Materials and methods
We assessed the association between plasma phospholipid fatty acids and breast cancer risk in a case–control study nested within the European Prospective Investigation into Cancer and Nutrition study. Sixty fatty acids were measured by gas chromatography in pre-diagnostic plasma phospholipids from 2982 incident breast cancer cases matched to 2982 controls. Conditional logistic regression models were used to estimate relative risk of breast cancer by fatty acid level. The false discovery rate (q values) was computed to control for multiple comparisons. Subgroup analyses were carried out by estrogen receptor (ER) and progesterone receptor expression in the tumours.
Results
A high level of palmitoleic acid [odds ratio (OR) for the highest quartile compared with the lowest OR (Q4–Q1) 1.37; 95% confidence interval (CI), 1.14–1.64; P for trend = 0.0001, q value = 0.004] as well as a high desaturation index (DI16) (16:1n–7/16:0) [OR (Q4–Q1), 1.28; 95% C, 1.07–1.54; P for trend = 0.002, q value = 0.037], as biomarkers of de novo lipogenesis, were significantly associated with increased risk of breast cancer. Levels of industrial trans-fatty acids were positively associated with ER-negative tumours [OR for the highest tertile compared with the lowest (T3–T1)=2.01; 95% CI, 1.03–3.90; P for trend = 0.047], whereas no association was found for ER-positive tumours (P-heterogeneity =0.01). No significant association was found between n-3 polyunsaturated fatty acids and breast cancer risk, overall or by hormonal receptor.
Conclusion
These findings suggest that increased de novo lipogenesis, acting through increased synthesis of palmitoleic acid, could be a relevant metabolic pathway for breast tumourigenesis. Dietary trans-fatty acids derived from industrial processes may specifically increase ER-negative breast cancer risk.

The past and future of ‘reported outcomes’ in studies on chemotherapy neuropathy

The manuscript by Park et al. in this issue of Annals of Oncology [1] reports on potential clinical and genetic prognostic factors of chemotherapy-induced peripheral neuropathy (CIPN). Predicting CIPN in individual patients, before symptoms manifest, is a critical goal that has not been achieved in the field. Even at the cohort level (a lesser challenge) available CIPN studies tend to disagree, regarding which predictors (genetic and otherwise) are significant. Therefore, additional clinical data are critically needed. We congratulate Park et al. on achieving this step: to put ICON7, a large, high-quality clinical trial, onto the 'map' of CIPN research.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Abstract
Background
Nanoparticle-drug conjugates enhance drug delivery to tumors. Gradual payload release inside cancer cells augments antitumor activity while reducing toxicity. CRLX101 is a novel nanoparticle–drug conjugate containing camptothecin, a potent inhibitor of topoisomerase I and the hypoxia-inducible factors 1α and 2α. In a phase Ib/2 trial, CRLX101 + bevacizumab was well tolerated with encouraging activity in metastatic renal cell carcinoma (mRCC). We conducted a randomized phase II trial comparing CRLX101 + bevacizumab versus standard of care (SOC) in refractory mRCC.
Patients and methods
Patients with mRCC and 2–3 prior lines of therapy were randomized 1 : 1 to CRLX101 + bevacizumab versus SOC, defined as investigator's choice of any approved regimen not previously received. The primary end point was progression-free survival (PFS) by blinded independent radiological review in patients with clear cell mRCC. Secondary end points included overall survival, objective response rate and safety.
Results
In total, 111 patients were randomized and received ≥1 dose of drug (CRLX101 + bevacizumab, 55; SOC, 56). Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2). In the clear cell population, the median PFS on the CRLX101 + bevacizumab and SOC arms was 3.7 months (95% confidence interval, 2.0–4.3) and 3.9 months (95% confidence interval 2.2–5.4), respectively (stratified log-rank P = 0.831). The objective response rate by IRR was 5% with CRLX101 + bevacizumab versus 14% with SOC (Mantel–Haenszel test, P = 0.836). Consistent with previous studies, the CRLX101 + bevacizumab combination was generally well tolerated, and no new safety signal was identified.
Conclusions
Despite promising efficacy data on the earlier phase Ib/2 trial of mRCC, this randomized trial did not demonstrate improvement in PFS for the CRLX101 + bevacizumab combination when compared with approved agents in patients with heavily pretreated clear cell mRCC. Further development in this disease is not planned.
Clinical trial identification
NCT02187302 (NIH).

ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe

Abstract
Background
The availability and affordability of safe, effective, high-quality, affordable anticancer therapies are a core requirement for effective national cancer control plans.
Method
Online survey based on a previously validated approach. The aims of the study were to evaluate (i) the availability on national formulary of licensed antineoplastic medicines across the globe, (ii) patient out-of-pocket costs for the medications, (iii) the actual availability of the medication for a patient with a valid prescription, (iv) information relating to possible factors adversely impacting the availability of antineoplastic agents and (v) the impact of the country's level of economic development on these parameters. A total of 304 field reporters from 97 countries were invited to participate. The preliminary set of data was posted on the ESMO website for open peer review and amendments have been incorporated into the final report.
Results
Surveys were submitted by 135 reporters from 63 countries and additional peer-review data were submitted by 54 reporters from 19 countries. There are substantial differences in the formulary availability, out-of-pocket costs and actual availability for many anticancer medicines. The most substantial issues are in lower-middle- and low-income countries. Even among medications on the WHO Model List of Essential Medicines (EML) the discrepancies are profound and these relate to high out-of-pocket costs (in low-middle-income countries 32.0% of EML medicines are available only at full cost and 5.2% are not available at all, and for low-income countries, the corresponding figures are even worse at 57.7% and 8.3%, respectively).
Conclusions
There is wide global variation in formulary availability, out-of-pocket expenditures and actual availability for most licensed anticancer medicines. Low- and low-middle-income countries have significant lack of availability and high out-of-pocket expenditures for cancer medicines on the WHO EML, with much less availability of new, more expensive targeted agents compared with high-income countries.

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma

Abstract
Background
In addition to inhibiting epidermal growth factor receptor (EGFR) signaling, anti-EGFR antibodies of the IgG1 'subtype' can induce a complementary therapeutic effect through the induction of antibody-dependent cell-mediated cytotoxicity (ADCC). Glycoengineering of therapeutic antibodies increases the affinity for the Fc-gamma receptor, thereby enhancing ADCC.
Patients and methods
We investigated the changes in immune effector cells and EGFR pathway biomarkers in 44 patients with operable, advanced stage head and neck squamous cell carcinoma treated with two preoperative doses of either glycoengineered imgatuzumab (GA201; 700 or 1400 mg) or cetuximab (standard dosing) in a neoadjuvant setting with paired pre- and post-treatment tumor biopsies.
Results
Significant antitumor activity was observed with both antibodies after just two infusions. Metabolic responses were seen in 23 (59.0%) patients overall. One imgatuzumab-treated patient (700 mg) achieved a 'pathological' complete response. An immediate and sustained decrease in peripheral natural killer cells was consistently observed with the first imgatuzumab infusion but not with cetuximab. The functionality of the remaining peripheral natural killer cells was maintained. Similarly, a pronounced increase in circulating cytokines was seen following the first infusion of imgatuzumab but not cetuximab. Overall, tumor-infiltrating CD3+ cell counts increased following treatment with both antibodies. A significant increase from baseline in CD3+/perforin+ cytotoxic T cells occurred only in the 700-mg imgatuzumab group (median 95% increase, P < 0.05). The most prominent decrease of EGFR-expressing cells was recorded after treatment with imgatuzumab (700 mg, –34.6%; 1400 mg, –41.8%). The post-treatment inflammatory tumor microenvironment was strongly related to baseline tumor-infiltrating immune cell density, and baseline levels of EGFR and pERK in tumor cells most strongly predicted therapeutic response.
Conclusions
These pharmacodynamic observations and relationship with efficacy are consistent with the proposed mode of action of imgatuzumab combining efficient EGFR pathway inhibition with ADCC-related immune antitumor effects.
Clinical trial registration number
NCT01046266 (ClinicalTrials.gov).

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Abstract
Background
B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b, noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin with/without paclitaxel (CetCis versus CetCisPac) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Patients and methods
Eligible patients had confirmed R/M SCCHN (oral cavity/oropharynx/larynx/hypopharynx/paranasal sinus) and no prior therapy for R/M disease. Cetuximab was administered on day 1 (2-h infusion, 400 mg/m2), then weekly (1-h infusions, 250 mg/m2). Cisplatin was given as a 1-h infusion (CetCis arm: 100 mg/m2; CetCisPac arm: 75 mg/m2) on day 1 of each cycle for a maximum of six cycles. Paclitaxel was administered as a 3-h infusion (175 mg/m2) on day 1 of each cycle. After six cycles, maintenance cetuximab was administered until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). We assumed a noninferiority margin of 1.40 as compatible with efficacy.
Results
A total of 201 patients were randomized 1 : 1 to each regimen; 191 were assessable. PFS with CetCis (median, 6 months) was noninferior to PFS with CetCisPac (median, 7 months) [HR for CetCis versus CetCisPac 0.99; 95% CI: 0.72–1.36, P =0.906; margin of noninferiority (90% CI of 1.4) not reached]. Median overall survival was 13 versus 11 months (HR = 0.77; 95% CI: 0.53–1.11, P =0.117). The overall response rates were 41.8% versus 51.7%, respectively (OR = 0.69; 95% CI: 0.38–1.20, P =0.181). Grade ≥3 adverse event rates were 76% and 73% for CetCis versus CetCisPac, respectively, while grade 4 toxicities were lower in the two-drug versus three-drug arm (14% versus 33%, P =0.015). No toxic death or sepsis were reported and cardiac events were negligible (1%).
Conclusion
The two-drug CetCis regimen proved to be noninferior in PFS to a three-drug combination with CetCisPac. The median OS of both regimens is comparable with that observed in EXTREME, while the life-threatening toxicity rate appeared reduced.
Clinical trial number
EudraCT# 2011-002564-24.

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools

Abstract
Background
Thymidylate synthase (TS) has a predictive role in pemetrexed treatment of mesothelioma; however, additional chemoresistance mechanisms are poorly understood. Here, we explored the role of the reduced-folate carrier (RFC/SLC19A1) and proton-coupled folate transporter (PCFT/SLC46A1) in antifolate resistance in mesothelioma.
Patients and methods
PCFT, RFC and TS RNA and PCFT protein levels were determined by quantitative RT-PCR of frozen tissues and immunohistochemistry of tissue-microarrays, respectively, in two cohorts of pemetrexed-treated patients. Data were analyzed by t-test, Fisher's/log-rank test and Cox proportional models. The contribution of PCFT expression and PCFT-promoter methylation to pemetrexed activity were evaluated in mesothelioma cells and spheroids, through 5-aza-2′-deoxycytidine-mediated demethylation and siRNA-knockdown.
Results
Pemetrexed-treated patients with low PCFT had significantly lower rates of disease control, and shorter overall survival (OS), in both the test (N = 73, 11.3 versus 20.1 months, P = 0.01) and validation (N = 51, 12.6 versus 30.3 months, P = 0.02) cohorts. Multivariate analysis confirmed PCFT-independent prognostic role. Low-PCFT protein levels were also associated with shorter OS. Patients with both low-PCFT and high-TS levels had the worst prognosis (OS, 5.5 months), whereas associations were neither found for RFC nor in pemetrexed-untreated patients. PCFT silencing reduced pemetrexed sensitivity, whereas 5-aza-2′-deoxycytidine overcame resistance.
Conclusions
These findings identify for the first time PCFT as a novel mesothelioma prognostic biomarker, prompting prospective trials for its validation. Moreover, preclinical data suggest that targeting PCFT-promoter methylation might eradicate pemetrexed-resistant cells characterized by low-PCFT expression.

Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial

Abstract
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of paclitaxel, with no reliable method to identify at-risk patients. We investigated the incidence and risk factors including genetic polymorphisms associated with the development of CIPN based on clinician and patient reporting of neuropathic symptoms.
Patients and methods
Risk factors for the development of CIPN were examined in 454 patients treated with paclitaxel/carboplatin from the International Collaboration on Ovarian Neoplasms 7 (ICON7) trial. Neuropathy was graded by clinicians by standard adverse event reporting and by patients utilising OV28 questionnaire. Genetic risk factors were examined by selecting six single nucleotide polymorphisms in genes associated with microtubule function. Risk factors were assessed via dose-to-event cox regression models.
Results
Grade >2 neuropathy was reported by clinicians in 28% of patients, while 67% of patients reported 'quite a bit' or 'very much' tingling or numbness. Agreement between clinicians and patients was poor (κ = 0.236, 95% confidence interval, 0.177–0.296, P < 0.001). Older age, bevacizumab treatment and bowel resection were associated with clinician reported CIPN, while older age and volume of residual disease were associated with patient-reported neuropathy. There were no significant associations between clinician-reported neuropathy or patient-reported neuropathy and TUBB2, CEP72 or individual MAPT or GSK3B SNPs, however MAPT additive polymorphisms were associated with patient-reported neuropathy and GSK3B additive polymorphisms were associated with clinician reported CIPN.
Conclusions
There was significant discordance between patient- and clinician-reported neurotoxicity. The lack of consensus regarding optimal outcome measures and whose opinion with regard to CIPN takes precedence is a limitation in the investigation of risk factors for CIPN. Care must be taken to select and include patient-reported outcome measures in CIPN assessment to enable accurate identification of genetic and other risk factors for neuropathy.

Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors

Tumor heterogeneity is a major challenge for drug development, and changes in heterogeneity are thought to contribute to anticancer treatment resistance. However, the standard diagnostic approach in clinical trials relies on analysis of a single (usually archival) sample from the primary tumor [1]. This provides limited characterization of a single tumor at initial diagnosis that is not necessarily representative of current disease status [1]. Recent studies have also highlighted challenges with intratumoral heterogeneity in advanced cancers [2, 3]. The success of targeted therapies is closely associated with identification of the target within a tumor sample. However, most tumors develop resistance due to intratumoral heterogeneity, clonal evolution, and selection pressure [1–4].

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Abstract
Background
Response rates in HER2-overexpressing EBC treated with neoadjuvant chemotherapy and trastuzumab (T) have been improved by addition of pertuzumab (P). The prospective, phase II, neoadjuvant WSG-ADAPT HER2+/HR− trial assessed whether patients with strong early response to dual blockade alone might achieve pathological complete response (pCR) comparable to that of patients receiving dual blockade and chemotherapy.
Patients and methods
Female patients with HER2+/HR− EBC (M0) were randomized (5:2) to 12 weeks of T + P ± weekly paclitaxel (pac) at 80 mg/m2. Early response was defined as proliferation decrease ≥30% of Ki-67 (versus baseline) or low cellularity (<500 invasive tumor cells) in the 3-week biopsy. The trial was designed to test non-inferiority for pCR in early responding patients of the T + P arm versus all chemotherapy-treated patients.
Results
From February 2014 to December 2015, 160 patients were screened, 92 were randomized to T + P and 42 to T + P+pac. Baseline characteristics were well balanced (median age 54 versus 51.5 years, cT2 51.1 versus 52.4%, cN0 54.3 versus 61.9%); 91.3% of patients completed T + P per protocol and 92.9% T + P+pac. The pCR rate in the T + P+pac arm was 90.5%, compared with 36.3% in the T + P arm as a whole. In the T + P arm, 24/92 were classified as non-responders, and their pCR rate was only 8.3% compared with 44.7% in responders (38/92) and 42.9% in patients with unclassified early response (30/92). No new safety signals were observed in the study population.
Conclusion
Addition of taxane monotherapy to dual HER2 blockade in a 12-week neoadjuvant setting substantially increases pCR rates in HER2+/HR− EBC compared with dual blockade alone, even within early responders to dual blockade. Early non-response under dual blockade strongly predicts failure to achieve pCR.

Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol

Abstract
Background
Breast cancer (BC) patients with comparable prognostic features have heterogeneous outcomes, party related to a possible radiotherapy resistance leading to local-regional recurrences (LRR). The objective of the present study was to identify predictive molecular biomarkers of LRR of BC.
Patients and methods
Genetic profile of 146 BC patients' tumours included in the ProfiLER clinical trial (NC01774409) between 2013 and 2016 were analysed using next-generation-sequencing and comparative-genomic-hybridization tests. Patients and tumour characteristics were retrospectively collected and analysed for association with genomic rearrangements (mutations, amplification, deletions). Only gene alterations observed in >3% of the tumours were selected.
Results
A total of 193 genomic rearrangements were identified, and 16 were observed in >3% of tumours. One was statistically correlated to the risk of local relapse. A median loco-regional progression-free survival (LRPFS) of 23.6 years was reported for PIK3CA mutation carriers (n = 31, 21.2%) versus 9.9 years for PIK3CA wild-type patients (HR 0.27, 95% CI 0.12–0.65, P =0.002 in univariate analysis). PIK3CA mutation was identified as an independent protective factor on LRR using multivariate analysis (HR 0.29, 95% CI 0.09–0.99, P =0.047). All other mutations, amplifications or deletions were not found associated with LRPFS.
Conclusion
PIK3CA mutation was associated with a lower risk of local relapse in this population of BCs. This is consistent with recent studies suggesting PIK3CA to be part of biological pathways impacting the radiosensitivity.

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3 -ITD, NPM1- or biallelic CEBPA mutations

Abstract
Background
The value of allogeneic hematopoietic cell transplantation (alloHCT) as postremission treatment is not well defined for patients with intermediate-risk acute myeloid leukemia (AML) without FLT3-ITD, biallelic CEBPA-, or NPM1 mutations (here referred to as NPM1mut-neg/CEBPAdm-neg/FLT3-ITDneg AML) in first complete remission (CR1).
Patients and methods
We addressed this question using data from two prospective randomized controlled trials on intensive induction- and risk-stratified postremission therapy. The NPM1mut-neg/CEBPAdm-neg/FLT3-ITDneg AML subgroup comprised 497 patients, aged 18–60 years.
Results
In donor versus no-donor analyses, patients with a matched related donor had a longer relapse-free survival (HR 0.5; 95% CI 0.3–0.9, P = 0.02) and a trend toward better overall survival (HR 0.6, 95% CI 0.3–1.1, P = 0.08) compared with patients who received postremission chemotherapy. Notably, only 58% of patients in the donor group were transplanted in CR1. We therefore complemented the donor versus no-donor analysis with multivariable Cox regression analyses, where alloHCT was tested as a time-dependent covariate: overall survival (HR 0.58, 95% CI 0.37–0.9, P = 0.02) and relapse-free survival (HR 0.51, 95% CI 0.34–0.76; P = 0.001) for patients who received alloHCT compared with chemotherapy in CR1 were significantly longer.
Conclusion
Outside clinical trials, alloHCT should be the preferred postremission treatment of patients with intermediate risk NPM1mut-neg/CEBPAdm-neg/FLT3-ITDneg AML in CR1.
Cinicaltrials.gov identifier
NCT00180115, NCT00180102

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer

Abstract
Background
Genomic changes that occur in breast cancer during the course of disease have been informed by sequencing of primary and metastatic tumor tissue. For patients with relapsed and metastatic disease, evolution of the breast cancer genome highlights the importance of using a recent sample for genomic profiling to guide clinical decision-making. Obtaining a metastatic tissue biopsy can be challenging, and analysis of circulating tumor DNA (ctDNA) from blood may provide a minimally invasive alternative.
Patients and methods
Hybrid capture-based genomic profiling was carried out on ctDNA from 254 female patients with estrogen receptor-positive breast cancer. Peripheral blood samples were submitted by clinicians in the course of routine clinical care between May 2016 and March 2017. Sequencing of 62 genes was carried out to a median unique coverage depth of 7503×. Genomic alterations (GAs) in ctDNA were evaluated and compared with matched tissue samples and genomic datasets of tissue from breast cancer.
Results
At least 1 GA was reported in 78% of samples. Frequently altered genes were TP53 (38%), ESR1 (31%) and PIK3CA (31%). Temporally matched ctDNA and tissue samples were available for 14 patients; 89% of mutations detected in tissue were also detected in ctDNA. Diverse ESR1 GAs including mutation, rearrangement and amplification, were observed. Multiple concurrent ESR1 GAs were observed in 40% of ESR1-altered cases, suggesting polyclonal origin; ESR1 compound mutations were also observed in two cases. ESR1-altered cases harbored co-occurring GAs in PIK3CA (35%), FGFR1 (16%), ERBB2 (8%), BRCA1/2 (5%), and AKT1 (4%).
Conclusions
GAs relevant to relapsed/metastatic breast cancer management were identified, including diverse ESR1 GAs. Genomic profiling of ctDNA demonstrated sensitive detection of mutations found in tissue. Detection of amplifications was associated with ctDNA fraction. Genomic profiling of ctDNA may provide a complementary and possibly alternative approach to tissue-based genomic testing for patients with estrogen receptor-positive metastatic breast cancer.

Anti-Desmoglein 1 IgG/IgA-Pemphigus in Verbindung mit einem Thymom



Virusreaktivierung täuscht Rezidiv des Pemphigus vulgaris bei einer immunsupprimierten Patientin vor



Dr. Christian Posch – Preisträger des Österreichischen Wissenschaftspreis der ÖGDV



Schwimmflossen-Vakuumversiegelung zur Behandlung plantarer Exzisionsdefekte



Ist eine komplette Lymphknotendissektion beim malignen Melanom mit positivem Sentinel notwendig?



Leserbrief zu Ebrahimi-Fakhari D et al. Dermatologische Manifestationen der tuberösen Sklerose (TSC). J Dtsch Dermatol Ges 2017; 15(7): 695–701.



Delayed-type hypersensitivity to oral and parenteral drugs

Summary

Adverse drug reactions of the delayed type rank among the most common dermatoses and are predominantly characterized by exanthematous macular or maculopapular eruptions. However, approximately 2 % of affected individuals develop severe or even life-threatening systemic immune reactions associated with organ involvement, requiring immediate diagnosis and treatment. Numerous drugs are capable of eliciting delayed-type hypersensitivity reactions, with antibiotics, anticonvulsant drugs, and the xanthine oxidase inhibitor allopurinol being the most common. Apart from genetic susceptibility, predisposing factors for the development of drug hypersensitivity reactions include high drug doses, polypharmacy, long treatment duration, female gender, as well as acute or chronic infections.



75 years after Erich Wagner's doctoral dissertation: “A Contribution to the Issue of Tattooing” – scientific misconduct in Nazi Germany



Off-Label-Use und Entscheidungen über Anträge auf Kostenübernahme in Deutschland – eine retrospektive Analyse

Zusammenfassung

Hintergrund und Zielsetzungen

Mit dem Begriff „Off-Label-Use" (zulassungsüberschreitende Anwendung) wird die Verordnung pharmazeutischer Präparate außerhalb ihrer zugelassenen Anwendungsgebiete beschrieben. Für seltene Krankheiten sind häufig keine oder kaum zugelassene Therapiealternativen verfügbar. Die Kosten für eine Off-Label Verordnung werden von der Gesetzlichen Krankenversicherung (GKV) nur unter bestimmten, gesetzlich geregelten Voraussetzungen übernommen. Um Regressforderungen durch die Kostenträger zu vermeiden, kann vor Verordnung ein Antrag auf Kostenübernahme ('Off-Label Antrag') gestellt werden.

Patienten und Methoden

Es wurde eine retrospektive Auswertung von Off-Label Anträgen, die im Zeitraum 2010-2012 in zwei Sprechstunden einer dermatologischen Hochschulambulanz gestellt wurden, durchgeführt (Autoimmun-Sprechstunde, Urtikaria-Sprechstunde). Krankenkassen, Bewilligungsraten, Gründe für Ablehnungen und die Bearbeitungsdauer wurden ausgewertet.

Ergebnisse

Die Auswertung ergab, dass 56,8 % der eingeschlossenen Off-Label Anträge (n = 44) initial bewilligt wurden. Nach bis zu zweimaligem Widerspruch gegen die Ablehnung einer Kostenübernahme betrug die Bewilligungsrate insgesamt 75 %. Die Dauer zwischen Antragstellung und Bescheid durch die Kostenträger betrug 49 Tage (Median). Bei positivem Bescheid erfolgte die Therapieeinleitung 92 Tage (Median) nach Antragstellung.

Schlussfolgerungen

Die vorliegende Fallserie zeigt, dass die Kostenträger den beantragten Kostenübernahmen für Off-Label Therapien im überwiegenden Teil der betrachteten Fälle zustimmten. Ob die identifizierten Probleme durch die gegenwärtigen Veränderungen der gesetzlichen Rahmenbedingungen (GKV-Versorgungsstrukturgesetz, Patientenrechtegesetz) adäquat adressiert werden, sollte in einer prospektiven Studie untersucht werden.



Dr. Kurt und Eva Herrmann-Stipendium in Höhe von 10.000 Euro für junge Dermatologinnen/Dermatologen



Rasche Entwicklung bilateraler Nekrosen der oberen Extremität



Sweet-Syndrom: Revision der diagnostischen Kriterien

Zusammenfassung

Die Diagnose des Sweet-Syndroms (SS) gründet sich auf eine Reihe von Kriterien, von denen mindestens zwei Haupt- und zwei Nebenkriterien erfüllt sein müssen. In einigen Fällen ist die Diagnose aufgrund des Fehlens bestimmter Kriterien jedoch nicht so einfach. Ziel der vorliegenden Studie war es, die klinischen, histopathologischen und Labormerkmale der aktuellen Diagnosekriterien für das SS zu überprüfen und ihre Aussagekraft anhand der publizierten Fälle sowie bei 40 in unserem Institut behandelten Patienten zu beurteilen. Unsere umfassende Prüfung der aktuellen Kriterien für das SS ergab, dass seit seiner Erstbeschreibung im Jahr 1964 die beiden Hauptkriterien bei allen Fällen – einschließlich unserer – durchweg vorhanden waren. Andererseits gab es hinsichtlich der Nebenkriterien deutliche Unterschiede zwischen den verschiedenen Studien und bei vielen Patienten war die Bedingung, dass zwei Nebenkriterien vorhanden sein müssen, nicht erfüllt. Wir schlagen hier zwei Gruppen von revidierten Diagnosekriterien für das SS vor. Dies geschieht mit dem Ziel, die Diagnose zu vereinfachen, Fehldiagnosen zu vermeiden und eine sofortige Behandlung zu ermöglichen. Die erste Gruppe umfasst konstante klinische und histopathologische Merkmale, die vorhanden sein müssen und die per se für die Diagnose eines SS ausreichen. Die zweite Gruppe enthält veränderliche Merkmale, deren Fehlen es nicht erlaubt, ein SS auszuschließen.



Penile ulcer in a 58-year-old HIV-positive patient after local injection of methamphetamine (crystal meth)



Kongresskalender 2017



Genitales Ulkus am Penis eines 58-jährigen HIV-positiven Patienten nach lokaler Injektion von Methamphetamin (Crystal Meth)



Quality of life assessment in patients with nonmelanoma skin cancer – psychometric validation of the EORTC QLQ-C30 questionnaire

Summary

Background

Nonmelanoma skin cancer (NMSC) is a chronic and sometimes difficult-to-treat condition affecting the quality of life (QL). The present study was conducted to investigate whether the European Organization for Research and Treatment of Cancer (EORTC) core QL Questionnaire – Cancer (QLQ-C30) is a suitable tool for the assessment of QL in patients with NMSC.

Patients and methods

In order to define the psychometric properties of the questionnaire, the QLQ-C30 and the Dermatology Life Quality Index (DLQI) were handed out to 172 patients of the Department of Dermatology at the University Hospital Regensburg, Germany.

Results

Internal consistencies of all multi-item scales (except one) were acceptable, with Cronbach's alpha ranging from 0.71 to 0.93. The hypothesized scale structure was supported by item/scale and interscale correlations within the QLQ-C30. Related scales of the QLQ-C30 and the DLQI correlated significantly, thus establishing construct validity. At the same time, the proportion of substantial correlations (6 % ≥ 0.40) indicated that the two questionnaires assessed distinct components of QL. The QLQ-C30 significantly differentiated between clinically distinct patient groups, indicating that severe clinical conditions were associated with greater impairment in physical, role, and cognitive functioning (p ≤ 0.030).

Conclusions

These results confirm the QLQ-C30 to be a suitable tool for the assessment of QL in patients with NMSC.



Wege zum Verständnis neutrophiler Dermatosen



Beurteilung der Lebensqualität bei Patienten mit nicht-melanozytärem Hautkrebs – psychometrische Validierung des EORTC QLQ-C30-Fragebogens

Zusammenfassung

Hintergrund

Nicht-melanozytärer Hautkrebs (NMSC, nonmelanoma skin cancer) ist eine chronische und mitunter schwierig zu behandelnde Erkrankung, die die Lebensqualität (LQ) beeinträchtigt. Die vorliegende Studie wurde durchgeführt um zu prüfen, ob der Kernfragebogen Quality of Life Questionnaire - Cancer (QLQ-C30) der European Organization for Research and Treatment of Cancer (EORTC) ein geeignetes Instrument für die Beurteilung der LQ bei NMSC-Patienten ist.

Patienten und Methoden

Zur Bestimmung der psychometrischen Eigenschaften des Fragebogens wurden der QLQ-C30 und der Dermatology Life Quality Index (DLQI) an 172 Patienten der Klinik und Poliklinik für Dermatologie des Universitätsklinikums Regensburg, Deutschland, ausgegeben.

Ergebnisse

Die interne Konsistenz aller Multi-Item-Skalen (außer einer) war akzeptabel, wobei Cronbachs Alpha-Koeffizient zwischen 0,71 bis 0,93 lag. Die angenommene Skalenstruktur wurde durch Korrelationen zwischen Items und Skalen sowie Korrelationen zwischen Skalen innerhalb des QLQ-C30 bestätigt. Verwandte Skalen des QLQ-C30 und des DLQI korrelierten signifikant und belegten damit die Konstruktvalidität. Gleichzeitig wies der Anteil substanzieller Korrelationen (6 % ≥ 0,40) darauf hin, dass mit den beiden Fragebogen unterschiedliche Aspekte der LQ beurteilt werden. Der QLQ-C30 differenzierte signifikant zwischen Patienten mit verschiedenen Erkrankungsgraden. Eine schwere Erkrankung ging mit stärkeren Beeinträchtigungen der Körperlichen, Rollen- und Kognitiven Funktion einher (p ≤ 0,030).

Schlussfolgerungen

Diese Ergebnisse bestätigen, dass der QLQ-C30 ein geeignetes Instrument für die Beurteilung der LQ bei NMSC-Patienten darstellt.



Kopfhautnekrose an Stirn und Schläfe



Flächige Hyperpigmentierungen im Gesicht einer philippinischen Patientin



EXTH-15. RADIATION-INDUCED LATE MALIGNANT MENINGIOMA TRANSFORMATION: CDK 4/6 INHIBITOR THERAPY

Abstract
Meningiomas are the most common primary brain tumor reported in the United States each year and account for approximately 30% of primary neoplasms. Though in most cases the etiology of meningiomas is unclear, prior exposure to radiation is responsible for a subset of meningiomas. Some have speculated that there may be a relationship between pretreatment characteristics and radiotherapy parameters in the development of radiation-induced meningiomas (RIM). Compared with their sporadic counterparts, currently, the clinical treatment involves is similar with radiation used as a first line therapy. Novel therapeutic agents being investigated in the treatment of these tumors, rely on the direct or cell cycle-mediated induction of DNA damage to promote cellular apoptosis. Our pre-clinical data showed that disruption of p16INK4a-Cdk4-Rb (retinoblastoma) pathways plays a significant role in the development of RIM in Rb+ low-gradelow-grade meningioma cells. These observations highlight the critical role of the p16INK4a-Cdk4-Rb pathway in RIM and suggest that targeting this pathway might be a promising strategy to improve the therapeutic efficacy among RIM patients. Pretreatment characteristics and radiotherapy parameters which may influence the time interval for development of radiation-induced Rb+ meningiomas (RIM) were identified. Our results also demonstrated that CDK 4/6 Inhibitor, significantly suppresses radiation induced malignant transformation and prolonged survival in a cell-free, slice culture model and xenograft model of meningioma. Success of the proposed therapeutic strategies in both in vitro and in vivo models may form the basis for future research.

ACTR-02. DCC-2618, A NOVEL pan-KIT AND PDGFRa KINASE SWITCH CONTROL INHIBITOR, SHOWS ENCOURAGING SIGNAL IN A PATIENT (PT) WITH GLIOBLASTOMA (GBM)

Abstract
BACKGROUND
Non-clinical data suggest that PDGFRa plays an important role in the development and progression of human gliomas. To date, few PDGFRa inhibitors with CNS activity have been available. DCC-2618 was designed to potently inhibit the broadest range of mutations (mut) in KIT & PDGFRa kinases that emerge during tumor progession or on treatment.
METHODS
In a dose-escalation study (NCT# 02571036) of oral DCC-2618 (QD or BID q28 days), pts with advanced malignancies with a molecular rationale for activity were eligible. MRI scans were performed initially every 2 cycles then every 3 cycles.
RESULTS
We enrolled 4 GBM pts and 1 anaplastic astrocytoma (AA) pt with PDGFRa muts/ amplifications who had progressed after standard temozolomide chemoradiation (GBM) or temozolomide only (AA) and had received 0 to 5 salvage therapies. Three pts (2 GBM and 1 AA) had a triple amplification of PDGFRa, KIT and KDR (4q12 amplicon). Two GBM pts had activating PDGFRa mutations. Pts were treated at 20 mg (1 pt), 50 mg BID (2 pts) or 100 mg QD (2 pts). The per-protocol population (N=48) received doses up to 200 mg BID and DCC-2618 was well tolerated. One GBM pt with mut PDGFRa progressed after 6 weeks and one stopped treatment due to a tumor-related hemaorrhage on C1D12. Two of the three pts with triple amplifications progressed after 2 cycles while the third pt (GBM, 20 mg BID) achieved a PR per RANO after 9 cycles. This pt is currently in cycle 20 with a remarkable 94% tumor reduction.
CONCLUSIONS
The durable partial response of >18 months in a GBM patient (94% tumor reduction) warrants further evaluation of DCC-2618 in gliomas. An expansion cohort for pts with KIT- and PDGFRa driven tumors was initiated to be able to better select the patient population with a likely benefit.

SCDT-20. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38

Abstract
INTRODUCTION
Children with diffuse intrinsic pontine gliomas (DIPGs) die within 2 years after initial diagnosis. The infiltrative nature and anatomic location of DIPGs in an eloquent area of the brain preclude surgical resection, and the blood-brain barrier (BBB) reduces the availability of systemically administered agents. In order to improve outcomes for patients with DIPG, new drug delivery approach circumventing the BBB are greatly needed. Intranasal delivery (IND) is a practical, noninvasive method to deliver therapeutic agents into the brain along with the olfactory and trigeminal nerves pathway. With the advantages of reducing systemic side effects and convenient self-administration for patients, IND is an alternative to systemic (intravenous) and/ or direct invasive (intraparechymal) drug delivery.
METHODS
Two human DIPG cell lines were treated with hydrophobic fluorophore (DiI)-labeled nanoparticle liposomes containing CPT-11 (nanoliposomal CPT-11) and SN-38. Cell viability was determined by MTS assay and intracellular localization was imaged by confocal microscopy. For in vivo study, mice bearing human brainstem gliomas were randomly assigned to 3 groups: 1. empty nanoliposomes, 2. nanoliposomal CPT-11, 3. nanoliposomal SN-38, administrating by IND for 3 weeks. In vivo distribution was determined by DiI-labeled nanoliposomal SN-38 into the tumor bearing mice. Tumor growth and response to therapy were quantitatively measured by bioluminescence imaging, and efficacy was assessed by survival analysis.
RESULTS
DiI-fluorescence were detected at 30 minutes and peaked at 24 hours following treatment with DiI nanoliposomal SN-38. Nanoliposomal SN-38 induced dose dependent inhibition of the growth of DIPG cells, that is greater inhibition than nanoliposomal CPT-11. IND of nanoliposomal SN-38 showed significant reduction of the growth rate in compared to IND of empty nanoliposome. Results from animal survival will be reported at the meeting.